Did Amphastar beat or miss consensus estimates last quarter?

What were the key takeaways from Amphastar's earnings call?

What guidance did Amphastar's management provide for the next earnings period?

What is Amphastar's gross profit margin?

What factors drove the changes in Amphastar's revenue and profit?

What does Amphastar do and what are its main business segments?

What is the market's earnings forecast for Amphastar next quarter?

What were the key takeaways from Amphastar’s earnings call?

- **Revenue Growth**: Q3 2025 net revenues $191.8M,-backed by 14% BAQSIMI and 11% Primatene MIST growth.
- **Pipeline Expansion**: $60B oncology/ophthalmology pipeline added via Nanjing Anji licensing.
- **Manufacturing Scale**: U.S. capacity quadrupling to support 50% proprietary products by 2026.
- **Financial Challenges**: 1.9% gross margin decline, $39.5M G&A spike due to litigation.
- **2026 Outlook**: High single to low double-digit growth, driven by AMP-007, AMP-015 launches.

**【Management Opening Remarks】**
- **Q3 2025 Financials**: Net revenues of $191.8 million, GAAP net income of $17.4 million, and non-GAAP EPS of $0.93. BAQSIMI sales grew 14% YoY to $53.6 million, while Primatene MIST increased 11% to $28.8 million.
- **Pipeline Expansion**: Acquired three novel peptide candidates (AMP-105, AMP-109, AMP-107) targeting oncology and ophthalmology, broadening the pipeline to a $60 billion market opportunity.
- **Manufacturing Growth**: U.S. production capacity to quadruple, supporting 50% proprietary product pipeline by 2026.
- **Regulatory Milestones**: FDA approval of iron sucrose injection ($2.4M Q3 sales) and upcoming launches of AMP-007 (mid-2026) and AMP-015 (H1 2026).

**【CFO Financial Commentary】**
- **Revenue Breakdown**: BAQSIMI (14% YoY), Primatene MIST (11% YoY), offset by declines in glucagon (-49%) and epinephrine (-12%) due to competition.
- **Gross Margin**: 51.4% (down 1.9% YoY) due to transition costs and competitive pricing.
- **Expenses**: Selling/marketing +28% to $11.5M, G&A +168% to $39.5M (litigation provision), R&D +6% to $22.4M (licensing fee).
- **Cash Flow**: $52.6M from operations, $4.9M share buybacks.

**【Q&A Highlights】**
- **2025 Guidance**: Flat revenue YoY, targeting high single to low double-digit growth in 2026.
- **Iron Sucrose**: Expected $2.4M/Q run rate, prioritizing profitability over market share.
- **Regulatory Delays**: FDA bandwidth impacts minor; AMP-007 launch on track for mid-2026.
- **Generic Competition**: Primatene MIST exclusivity until 2026; generics unlikely due to low margins and brand loyalty.
- **New Peptides**: Early-stage development with potential for accelerated approval based on preclinical data.

Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2025 Earnings Call Transcript

- **Topline Growth Driven by BAQSIMI**: 21% YoY sales to $46.7M, offsetting legacy product declines
- **Flat 2025 Sales Guidance**: Risk-adjusted for 2 potential approvals; BAQSIMI growth key to offsetting competition
- **Manufacturing Expansion**: $100M U.S. capacity expansion to support proprietary pipeline and supply chain resilience
- **Regulatory Momentum**: AMP-002 near-term approval optimism; AMP-015 on track for Q4 2025 GDUFA
- **R&D Focus**: 14% YoY investment in complex injectables and interchangeable biosimilars
- **Margin Pressure**: 49.6% gross margin vs 52.2% YoY, driven by competition in glucagon/epinephrine markets

**【Management Opening Remarks】**
- **Revenue Performance**: Q2 2025 net revenues of $174.4 million, driven by BAQSIMI sales growth of 21% YoY to $46.7 million. Primatene MIST remained stable at $22.9 million, while legacy products faced competition-driven declines.
- **BAQSIMI Success**: Full global commercialization since Q1 2025, with unit volume and ASP increases. BAQSIMI now accounts for 27% of total revenue.
- **Manufacturing Expansion**: $100 million investment to quadruple California facility capacity, enhancing U.S. supply chain resilience and supporting R&D pipeline.
- **Pipeline Progress**: 
  - AMP-002 (FDA review ongoing; optimistic for near-term approval)
  - AMP-007 (inhalation filing with GDUFA date Q1 2026)
  - AMP-015 (teriparatide; Q4 2025 GDUFA date)
  - AMP-018 (GLP-1 ANDA; CRL response due Q4 2025)
  - AMP-004 (interchangeable insulin aspart BLA; regulatory precedent set by recent competitor approval)
- **R&D Investment**: $20.1 million (14% YoY increase), focused on complex injectables and proprietary products.

**【CFO Financial Commentary】**
- **Revenue Trends**: Q2 2025 revenue down 4% YoY ($174.4M vs $182.4M), with BAQSIMI offsetting legacy product declines. Epinephrine PFS sales dropped 42% due to new competitor entry.
- **Gross Margin**: 49.6% (vs 52.2% YoY), impacted by Viatris transition costs and pricing erosion in glucagon/epinephrine markets.
- **Expense Management**: 
  - S&M +14% ($10.2M) due to BAQSIMI co-promotion
  - G&A +5% ($14M) from personnel costs
  - R&D +14% ($20.1M) for pipeline advancement
- **Liquidity**: $35.6M operating cash flow; $39.2M share buybacks completed, with $50M new authorization.

**【Q&A Highlights】**
1. **Revenue Guidance**: Flat YoY sales expected, with 2 potential approvals (AMP-002, AMP-015) contributing risk-adjusted $10-15M each.
2. **BAQSIMI Outlook**: High single-digit unit growth and 3% ASP increase maintained; MannKind collaboration driving HCP engagement.
3. **Competitive Dynamics**: 
  - Glucagon: 2 new competitors expected Q3 2025; market shift to ready-to-use products
  - Epinephrine PFS: Pricing and volume declines stabilized
4. **Manufacturing Strategy**: U.S.-based production for all finished products; expansion supports proprietary pipeline (AMP-004, AMP-007)
5. **Pipeline Risk/Reward**: 
  - AMP-007: Potential first-to-market opportunity
  - AMP-018: Expect modest contribution due to crowded generic market
  - AMP-004: Long-term interchangeable insulin aspart leader position

Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2025 Earnings Call Transcript

- **Top Line Resilience**: Q1 2025 revenue flat (-1%) despite 20% growth in Primatene MIST and 177% surge in BAQSIMI sales.
- **Margin Challenges**: Gross margin compression (50% vs 52.4%) driven by BAQSIMI distribution shift and pricing pressures.
- **Pipeline Momentum**: 3 key products (AMP-002, 007, 015) on track for 2025 contributions; AMP-004 BLA accepted with 2026 approval target.
- **BAQSIMI Growth**: High single-digit unit growth expected, with Q2 IQVIA data showing accelerating momentum.
- **Strategic Positioning**: U.S. manufacturing mitigates tariff risks; interchangeable insulin biosimilar creates $1.4B market opportunity.

**【Management Opening Remarks】**
- Q1 2025 net revenue: $170.5 million (-1% YoY), driven by soft demand in critical care products (Dextrose, Epinephrine) and increased competition in Glucagon and Epinephrine markets.
- BAQSIMI sales: $38.3 million (177% YoY growth), with full operational control transferred from Lilly.
- Primatene MIST sales: $29 million (+20% YoY), benefiting from expanded physician sampling programs.
- Pipeline highlights: AMP-002 FDA communication resolved within 1 day, AMP-007 CRL response due Q2, and AMP-004 BLA accepted with 2026 approval target.

**【CFO Financial Review】**
- Gross margin: 50% (down from 52.4% YoY) due to BAQSIMI distribution shift and pricing declines on high-margin Epinephrine vials.
- Operating expenses: +27% YoY in sales/marketing (BAQSIMI co-promotion with MannKind) and +18% in R&D (FDA filing fees).
- Net income: $25.3 million (-41% YoY) due to higher expenses and one-time tariff impacts ($500k/Q4+).
- Cash flow: $35.1 million from operations, with $11 million share buybacks.

**【Q&A Key Takeaways】**
- **Pipeline Expectations**: 2025 flat revenue guidance assumes contributions from AMP-002, AMP-007, and AMP-015 (FDA action dates Q4 2025). AMP-007 CRL response due Q2, potential approval by year-end.
- **BAQSIMI Growth**: High single-digit unit growth expected in 2025, supported by expanded sales force and MannKind partnership. Q1 2025 IQVIA data shows low double-digit weekly growth in Q2.
- **Tariff Impact**: Current $500k/Q impact manageable; U.S. manufacturing position advantageous if tariffs focus on finished products.
- **Competitive Pressures**: Glucagon and Epinephrine markets face new entrants; Dextrose and Enoxaparin facing generic competition.
- **Insulin Interchangeability**: AMP-004 BLA targets being first interchangeable biosimilar, with $1.4 billion market opportunity.


Amphastar Pharmaceuticals (AMPH)-7 May 25-2025 Q1 Earnings call transcript

- **Revenue Milestones**: 2024 revenue up 14% to $732M, with Primatene Mist hitting $102M annual sales.
- **Strategic Expansion**: BAQSIMI fully transitioned to Amphastar, and MannKind partnership doubles sales reach.
- **Pipeline Progress**: 4 key products on track for 2025 approvals; AMP-002 delayed to 2026.
- **Growth vs. Challenges**: High single-digit Primatene Mist growth offset by glucagon/epinephrine declines; gross margin pressure expected in 2025.
- **Cash Flow Strength**: $213.4M annual operating cash flow used for expansion and buybacks.

**【CEO Opening Remarks】**
- **Revenue Milestones**: 2024 annual revenue reached $732 million (+14% YoY), with Q4 at $186 million (+5% YoY). Primatene Mist achieved $102 million in annual sales, surpassing the $100 million goal set 3 years ago.
- **Strategic Growth Drivers**: BAQSIMI sales transitioned fully to Amphastar, and a new partnership with MannKind expanded sales reach. Primatene Mist's pilot sales program targets primary care physicians to enhance market penetration.
- **Pipeline Progress**: 4 key products (AMP-002, AMP-007, AMP-015, AMP-018) have GDUFA dates in 2025. AMP-015 responded to a CRL, while AMP-007 and AMP-018 are on track for Q2 approvals.
- **Regulatory Resilience**: Despite delays with AMP-002, discussions with FDA continue, and the insulin BLA (AMP-104) was refiled with focus on interchangeability.

**【CFO Financial Breakdown】**
- **Q4 Financials**: Revenue $186.5M (+5% YoY). BAQSIMI contributed $41.8M, Primatene Mist $28.9M (+18% YoY). Glucagon sales declined to $25.6M (-18% YoY) due to competition.
- **Gross Margin Dynamics**: 46.5% (Q4 2024) vs. 54% (Q4 2023), driven by BAQSIMI cost absorption and higher labor/component costs.
- **Expense Management**: R&D down 11% to $18.1M, while S&M up 21% to $10.4M due to BAQSIMI marketing.
- **2025 Outlook**: Flat sales growth with high single-digit Primatene Mist growth offset by glucagon/epinephrine declines. Gross margin pressure from pricing and product mix.
- **Cash Flow**: $213.4M annual operating cash flow, used for expansion and stock buybacks.

**【Q&A Highlights】**
- **Primatene Mist & Glucagon**: High single-digit growth expected for Primatene Mist; glucagon sales to decline due to competition shift to BAQSIMI.
- **BAQSIMI Collaboration**: MannKind's sales force doubles reach, targeting endocrinologists. Unit growth in high single-digits with 3% price increase in the U.S.
- **Pipeline Execution**: 2 product launches risk-adjusted for Q4 2025; AMP-002 likely delayed to Q1 2026.
- **Market Competition**: Epinephrine prefilled syringe remains exclusive; Pfizer's return to market uncertain.


Amphastar Pharmaceuticals (AMPH)-27 Feb 25-2024 Q4 Earnings call transcript

Amphastar Pharmaceuticals (AMPH)-6 Nov 24-2024 Q3 Earnings call transcript

Amphastar Pharmaceuticals (AMPH)-7 Aug 24-2024 Q2 Earnings call transcript

Amphastar Pharmaceuticals (AMPH)-8 May 24-2024 Q1 Earnings call transcript

Amphastar Pharmaceuticals (AMPH)-28 Feb 24-2023 Q4 Earnings call transcript

- **Revenue Surge**: Q3 revenue up 50% to $180.5 million, fueled by BACSIMI and core product strength.
- **Product Momentum**: Glucagon sales +107%, Primatene Mist +35%, leveraging competitor shortages.
- **Financial Health**: Net income $49.2 million (+200% YoY), 60% gross margin, $64.3 million cash flow.
- **Strategic Moves**: BACSIMI U.S. launch Q1 2024, $200 million debt reduction, intranasal oxycodone delayed due to shortage prioritization.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 revenue of $180.5 million, up 50% YoY, driven by BACSIMI acquisition and core product strength.
- **Key Product Performance**: Glucagon sales surged 107% to $29.5 million, Primatene Mist reached $24.8 million (35% YoY growth), and epinephrine sales rose 19% to $20.2 million.
- **Strategic Acquisitions**: BACSIMI distribution begins Q1 2024 in the U.S., with global rollouts pending regulatory transfers.
- **Shortage Benefits**: Lidocaine and epinephrine sales grew 10% and 19% respectively, leveraging competitor supply shortages.

**【CFO Financial Commentary】**
- **Financial Highlights**: GAAP net income $49.2 million ($0.91 EPS), up 200% YoY. Adjusted EPS $1.15, reflecting $61.9 million adjusted net income.
- **Gross Margin Expansion**: 60% gross margin driven by high-margin products like glucagon and Primatene Mist.
- **Vaccine Contribution**: $28.7 million net economic benefit from BACSIMI, with full distribution to begin in 2024.
- **Expense Management**: Selling expenses rose 34% to $6.4 million due to BACSIMI marketing, offset by $64.3 million cash flow from operations.
- **Debt Optimization**: $200 million term loan paid down, with $50 million share buyback and interest rate hedging reducing future expenses.

**【Q&A Highlights】**
- **BACSIMI Outlook**: Q3 sales $48.7 million (31% of annual sales), with 2024 peak target $250-275 million. U.S. distribution starts Q1 2024, global rollouts follow.
- **Shortage Impact**: Lidocaine, dextrose, and epi syringes shortages expected to persist into Q2 2024, delaying intranasal oxycodone launch.
- **Gross Margin Sustainability**: 60% gross margin driven by high-margin products, but future vaccine sales will include COGS.
- **Sales Force Strategy**: Contract and internal sales teams launched Q4 2023, with ongoing expansion based on market demand.

AMPH

AMPH fundamentals

Earnings Call

You can ask Aime